metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-88 rs641738 MBOAT7 POLYMORPHISM AS A PREDICTOR OF FIBROSIS IN METABOLIC DYSFUN...
Journal Information
Vol. 29. Issue S3.
Abstracts of the 2024 Annual Meeting of the ALEH
(December 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S3.
Abstracts of the 2024 Annual Meeting of the ALEH
(December 2024)
Full text access
P-88 rs641738 MBOAT7 POLYMORPHISM AS A PREDICTOR OF FIBROSIS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Visits
30
Sofia Rocha1, Claudia P. Oliveira2, José Tadeu Stefano2, Raymundo Soares Azevedo3, Isabel Veloso Alves Pereira2, Michele Gouvea1, Patrícia Momoyo Zitelli4, Mário Guimarães Pessoa4, João Renato Rebello Pinho1
1 Laboratório de Gastroenterologia e Hepatologia Tropical - LIM07, Instituto de Medicina Tropical, Faculdade de Medicina, Universidade de São Paulo, Brasil
2 Laboratório de Gastroenterologia Clínica e Experimental - LIM07, Hospital das Clínicas HCFMUSP, Departamento de Gastroenterologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil
3 Departamento de Patologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil
4 Departamento de Gastroenterologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (1)
Special issue
This article is part of special issue:
Vol. 29. Issue S3

Abstracts of the 2024 Annual Meeting of the ALEH

More info
Conflict of interest

No

Introduction and Objectives

Recent studies have indicated that certain polymorphisms may be associated with the progression of metabolic dysfunction-associated steatotic liver disease (MASLD).

To construct a predictive fibrosis score and evaluate the association of the risk genetic polymorphisms rs738409 PNPLA3, rs58542926 TM6SF2, rs641738 MBOAT7, rs1260326 and rs780094 GCKR, rs72613567 HSD17B13 and rs2642438 MARC1 in MASLD.

Patients / Materials and Methods

This cross-sectional and retrospective study analyzed 212 biopsy-proven MASLD patient samples from the Hospital das Clínicas, Faculty of Medicine, University of São Paulo. Samples were divided into two groups: Group 1: absent and mild fibrosis (F0-1, n=113) and Group 2: significant and advanced fibrosis (F2-4, n=99). Demographic, laboratory, and histological data were compared, along with their association and frequency with the polymorphisms. Genotyping was performed by real-time PCR allele discrimination, and statistical analysis was conducted using Jasp® and Jamovi® software. The significance level adopted was 5%.

Results and Discussion

Most patients were female (146; 68.9%) with an average age of 56 years and were obese (BMI of 30.7). Group 1 had a higher frequency of dyslipidemia and NAS score 0-4 (71%), higher total cholesterol levels, and lower levels of AST, ALT, GGT, and alpha-fetoprotein compared to Group 2 (p < 0.05). The regression model (ROC Curve) used the TT genotype of the MBOAT7 gene associated with age, ALT, AST, GGT, TG, HDL, LDL, and total cholesterol to predict fibrosis (AUC: 0.77; Sen: 0.61; Spe: 0.79; Acc: 0.71; R²: 0.14) (Fig. 1A). Another model with AFP (n = 76) showed (AUC: 0.80; Sen: 0.67; Spe: 0.83; Acc: 0.76; R²: 0.24) (Fig. 1B). The polymorphisms of the PNPLA3, TM6SF2, GCKR, HSD17B13, and MARC1 genes did not demonstrate risk or protection in this cohort.

Conclusions

This study underscores the rs641738 MBOAT7 polymorphism as a potential predictor of fibrosis in MASLD, highlighting its value in clinical assessment and management.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos